Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-28T18:57:34.083Z Has data issue: false hasContentIssue false

Obesity and diabetes: the link between adipose tissue dysfunction and glucose homeostasis

Published online by Cambridge University Press:  09 December 2015

Monise Viana Abranches*
Affiliation:
Instituto de Ciências Biológicas e da Saúde, Universidade Federal de Viçosa Campus de Rio Paranaíba, Rodovia MG-230 – Km 7, Rio Paranaíba, MG, 38810-000, Brazil
Fernanda Cristina Esteves de Oliveira
Affiliation:
Departamento de Enfermagem, Faculdade de Ciências Sociais Aplicadas de Sinop, Sinop, MT, 78550-000, Brazil
Lisiane Lopes da Conceição
Affiliation:
Departamento de Nutrição e Saúde, Universidade Federal de Viçosa, Campus Universitário, Edifício Centro de Ciências Biológicas II, s/n, Viçosa, MG, 36571-900, Brazil
Maria do Carmo Gouveia Peluzio
Affiliation:
Departamento de Nutrição e Saúde, Universidade Federal de Viçosa, Campus Universitário, Edifício Centro de Ciências Biológicas II, s/n, Viçosa, MG, 36571-900, Brazil
*
*Corresponding author: M. V. Abranches, email monise.abranches@ufv.br
Rights & Permissions [Opens in a new window]

Abstract

Obesity and type 2 diabetes mellitus (T2DM) epidemics, which have already spread, imply the possibility of both conditions being closely related. Thus, the goal of the present review was to draw a parallel between obesity, adipose tissue (AT) changes, and T2DM development. To this end, a search was conducted in PubMed, MEDLINE and SciELO databases, using the following key words and their combinations: obesity; diabetes; insulin resistance; diet; weight loss; adipocin; inflammation markers; and interleukins. Based on a literature review, AT dysfunction observed in obesity is characterised by adipocyte hypertrophy, macrophage infiltration, impaired insulin signalling and insulin resistance. In addition, there is release of inflammatory adipokines and an excessive amount of NEFA promoting ectopic fat deposition and lipotoxicity in muscle, liver and pancreas. Recent evidence supports the hypothesis that the conception of AT as a passive energy storage organ should be replaced by a dynamic endocrine organ, which regulates metabolism through a complex adipocyte communication with the surrounding microenvironment. The present review demonstrates how glucose homeostasis is changed by AT dysfunction. A better understanding of this relationship enables performing nutritional intervention strategies with the goal of preventing T2DM.

Type
Review Article
Copyright
Copyright © The Authors 2015 

Introduction

Obesity is the chronic and excessive accumulation of body fat and, due to its high prevalence in various locations in the world, is considered a pandemic(Reference Goossens1). It predisposes increased risk of premature morbidity and mortality, since there is a relationship between the increase in BMI and related diseases, such as hypertension, type 2 diabetes mellitus (T2DM) and CVD(Reference Goyal, Nimmakayala and Zonszein2).

Currently, obesity is characterised by a metabolic process associated with low-intensity chronic inflammation, which is evidenced by an increased concentration of circulating inflammatory mediators in an asymptomatic form(Reference White, Damm and Hancock3Reference Geraldo and Alfenas5). In addition to the functions of mechanical protection of organs, body temperature control and energy storage, adipose tissue (AT) is also considered an active endocrine organ. It is able to send and respond to signals in order to modulate appetite, energy intake, insulin sensitivity, the endocrine and reproductive system, bone metabolism and inflammation, among other functions(Reference Forsythe, Wallace and Livingstone4, Reference Ramalho and Guimarães6Reference Frühbeck, Méndez-Giménez and Fernández-Formoso9).

More than fifty inflammatory proteins have been linked to obesity and its co-morbidities, and the mechanisms by which these proteins influence the manifestation of these diseases seem to involve the attenuation of insulin activity, fat mobilisation, endothelial dysfunction and oxidative stress(Reference Geraldo and Alfenas5). On the other hand, it has also been suggested that reduction in weight and body fat percentage can decrease the concentration of circulating pro-inflammatory molecules and increase anti-inflammatory molecules(Reference Forsythe, Wallace and Livingstone4, Reference Ramalho and Guimarães6).

Based on the above-mentioned considerations, the goals of the present review were drawing a parallel between changes in AT, the genesis of obesity and the development of T2DM, and discussing whether the reduction in risk of co-morbidities resulting from body-weight reduction may be due to a decrease in pro-inflammatory factors.

A search was conducted using PubMed, MEDLINE and SciELO scientific databases with the following key words and their combinations: obesity; diabetes; insulin resistance; diet; weight loss; adipocin; inflammation markers; and interleukins. Reviews were consulted in order to clarify the mechanisms involved in the pathogenesis of obesity and insulin resistance.

Adipose tissue: a lipid storage organ

Positive energy balance leads to adipocyte hypertrophy and hyperplasia. In the context of obesity, even though AT may have a strategic protector effect, it can also be considered dangerous when in excess(Reference Goyal, Nimmakayala and Zonszein2). Despite the clinical importance of obesity, knowledge about its origin, development and functions related to AT is still limited.

Origin of adipose tissue

AT is the primary site for the storage of energy and it also functions as an endocrine organ that regulates energy homeostasis via secretion of adipokines, such as adiponectin, leptin and resistin(Reference Crossno, Majka and Grazia10, Reference Majka, Fox and Psilas11). Although the origin and development of adipocytes are not completely elucidated, the functions of AT under normal conditions and adverse effects of excessive adiposity linked to weight gain can be related to these biological markers(Reference Crossno, Majka and Grazia10).

Only white AT was taken into consideration in the present review, because the adipocytes that compose it are especially involved in obesity. The development of AT begins during pregnancy in higher mammals, and shortly after birth in rodents. Dense regions of mesenchymal cells linked to vascular structures form the sites where AT is developed. Depending on the epigenetic event, multipotent mesenchymal stem cells turn into unipotent adipoblast cells, and the latter turn into pre-adipocytes(Reference Billon, Kolde and Reimand12, Reference Dudakovic, Camilleri and Lewallen13). According to the stimulus, pre-adipocytes suffer adipogenic conversion, i.e. they accumulate lipids in a single lipid droplet and become sensitive to insulin, thus being called functional or mature adipocytes(Reference Billon, Kolde and Reimand12).

In addition to the adipocytes and their precursors, AT contains a matrix formed by collagenous and reticular fibres, nerve cells, blood vessels, lymph nodes, immune cells (leucocytes, macrophages) and fibroblasts(Reference Fonseca-Alaniz, Takada and Alonso-Vale14). A study conducted by Dudakovic et al. (Reference Dudakovic, Camilleri and Riester15) revealed that mesenchymal stem cells from AT spontaneously express fibroblastic, osteogenic, chondrogenic and adipogenic biomarkers when kept in confluent cell cultures, which demonstrates their versatility.

The stimuli for adipogenesis in AT-derived stem cells result in increased activity of glycerol-3-phosphate dehydrogenase, which is a lipogenic enzyme involved in the synthesis of TAG. In addition, so that adipocytes become mature, AT-derived stem cells increase the expression of other proteins involved the biosynthesis and storage of lipids, such as: lipoprotein lipase (LPL), which is an exchange enzyme; PPARγ, a transcription factor that causes pre-adipocyte differentiation; adipocyte fatty acid binding protein (aP2); glucose transporter GLUT; and leptin(Reference Perrini, Cignarelli and Ficarella16).

AT can expand throughout life in response to increased food intake resulting in adipocyte hypertrophy due to the accumulation of TAG. Still, there may be hyperplasia due to resident pre-adipocyte differentiation and mesenchymal progenitor cells in new adipocytes (Fig. 1). AT mass also increases in response to treatment with thiazolidinediones (TZD) used clinically as anti-diabetogenic agents. These agents stimulate the emergence of new adipocytes by activating the nuclear receptor PPARγ. Weight gain and treatment with TZD are associated with changes in circulating concentration of cytokines and chemotactic factors (CCR2, CXCL10 and RANTES) that can regulate progenitor cell mobilisation, trafficking and recruitment(Reference Crossno, Majka and Grazia10).

Fig. 1 Influence of positive energy balance on adipogenesis. An excess of energy nutrients makes pre-adipocytes increase the expression of mediators associated with the accumulation of intracellular TAG transforming them into mature adipocytes. GPDH, glycerol-3-phosphate dehydrogenase; LPL, lipoprotein lipase; aP2, adipocyte protein 2 – carrier protein for fatty acids.

Even though there is consensus on the origin of adipocytes from mesenchymal progenitor cells residing in AT, some studies have shown that mesenchymal stem cells and multipotent progenitor cells can be isolated from other tissues and induced to adipocyte differentiation in vitro and in vivo (Reference Majka, Fox and Psilas11, Reference Bosnakovski, Mizuno and Kim17Reference Peister, Mellad and Larson19). Thus, distinct populations of adipocytes may be identified in AT from different regions of the body.

Functional variations between white fatty tissues can result from specific differences between the progenitors of these fat deposits. Crossno et al. (Reference Crossno, Majka and Grazia10) assessed whether bone marrow progenitor cells could contribute to the development of new adipocytes in AT through bone marrow transplantation from transgenic mice expressing green fluorescent protein (GFP) to C57BL6 wild-type mice subjected to treatment with a hyperlipidic diet or rosiglitazone for 8 weeks. The analyses revealed the presence and the increase in GFP+ multilocular adipocytes in both treatments. In turn, these adipocytes expressed adiponectin, perilipin, fatty acid-binding protein, leptin and PPARγ, but not uncoupling protein-1, a marker of the CD45 haematopoietic line. The authors concluded that bone marrow-derived progenitor cells can traffic to AT and differentiate into adipocytes.

Tang et al. (Reference Tang, Zeve and Suh20) found a subpopulation of stromal–vascular cells expressing PPARγ, i.e. a marker of newly formed adipocytes. In addition, the authors assessed the adipogenic potential of these cells when subjected to spontaneous adipogenesis or stimulation by insulin. This procedure revealed that blood vessels of AT seem to function as an adipocyte progenitor niche and may provide signs for their development.

Changes in adiposity with modification of body fat distribution, AT metabolism and inflammation profile are also associated with age, weight gain and sex. These changes especially with respect to visceral fat may be linked to obesity-related co-morbidities, particularly to T2DM. According to a study conducted by Majka et al. (Reference Majka, Fox and Psilas11), bone marrow-derived adipocytes accumulate in a specific way and according to sex in certain regions of the body. The researchers affirm that this differential accumulation emphasises gene expression patterns in adipocytes derived from bone marrow precursors, which exhibited reduced expression of mitochondrial and peroxisomal genes related to the biogenesis of these organelles and lipid oxidation, and increased expression of genes encoding pro-inflammatory cytokines.

These results challenge the paradigm of a resident mesenchymal origin for white AT adipocytes and point out that adipocytes may be originated from bone marrow-derived progenitor cells. Moreover, they reveal that the different subpopulations of adipocytes may perform specific roles according to sex and the physiological changes that occur in the stages of life. Thus, adipocyte precursor cells are indeed heterogeneous cell populations, and this is the origin potentially associated with the various functions that AT can exert and the sites in which it can expand.

Development of adipose tissue via PPARγ: molecular considerations

It is known that the functions of AT are altered in obese individuals with insulin resistance. In addition, morphological changes, associated with hyperglycaemia and the beginning of T2DM, are also observed in adipocytes(Reference Sharma and Staels21).

The great interest of researchers in studying PPARγ is due to its high expression in AT, its relevant role in adipogenesis, and the possibility of its induction serving as a model system to study transcriptional and epigenetic regulation of genes expressed in specific cell types(Reference Lee and Ge22). In pre-adipose cell lines, the expression of PPARγ during cellular differentiation has been associated with lipid accumulation and the expression of genes involved in adipogenesis, such as aP2, LPL and adipsin. PPARγ also induced the differentiation of pre-adipocytes in mature cells from human subcutaneous AT concomitantly with the activation of genes involved in TAG synthesis and storage(Reference Sharma and Staels21).

PPARγ can also play an important role in the regulation of lipogenesis; however, this mechanism has not yet been elucidated. Kubota et al. (Reference Kubota, Terauchi and Miki23) tried to understand this process by studying PPARγ(+/–)-deficient mice fed on a hyperlipidic diet. The authors found that these animals had gained less weight and had less AT when compared with those of the control group. Genes under transcriptional control of PPARγ in AT include genes encoding enzymes involved in the metabolism of fatty acids, such as LPL, acyl-CoA synthase and FAT/CD36 (cluster of differentiation 36 – known as fatty acid translocase), suggesting that PPARγ plays an important role in lipid uptake by adipocytes(Reference Kersten24). Way et al. (Reference Way, Harrington and Brown25) studied the effects of GW 1929 (PPARγ agonist) on glucose and TAG concentrations and the expression of genes in diabetic and obese Zucker rats. The treatment led to reductions in NEFA, glucose and TAG concentrations. In addition, the authors confirmed an increased expression of genes involved in lipogenesis, such as acetyl-CoA carboxylase, fatty acid synthase and ATP-citrate lyase.

In addition to its role in lipogenesis, PPARγ can also contribute to the inhibition of genes such as the one that encodes leptin through lipolysis activation and fatty acid oxidation(Reference Kersten, Mandard and Escher26, Reference Spiegelman and Enerbäck27). Kadowaki et al. (Reference Kadowaki, Hara and Yamauchi28) assessed the expression of PPARγ and leptin concentration in mice with and without this receptor deficiency when fed on a fat-rich diet. It was observed that the PPARγ-deficient group exhibited an increase in leptin concentration, in addition to the adipocytes being smaller. These results indicate that PPARγ can assist in the regulation of obesity and insulin resistance, since its low expression stimulates lipolysis and hinders glucose uptake.

Lipid accumulation and development of type 2 diabetes mellitus

TAG deposited in AT serve as high-density energy fuel and corresponds to 85 % of adipocyte weight(Reference Trayhurn29). AT is crucial for reducing the influx of dietary fat that reaches the circulation daily, since it suppresses the release of NEFA into the blood and increases TAG clearance(Reference Goossens1).

In obesity, lipid storage capacity is reduced, especially in the postprandial period. This process probably occurs because the volume of adipocytes in obese individuals has already reached its limit and cannot accumulate TAG efficiently. Added to this, there is an increase in the rate of lipolysis during the fasting period(Reference Frühbeck, Méndez-Giménez and Fernández-Formoso9). As a result, other tissues are exposed to excessive NEFA influx(Reference Goossens1), thus compromising their functions. The processes derived from lipid accumulation in the bloodstream are illustrated in Fig. 2.

Fig. 2 Accumulation of NEFA in the blood and relationship with type 2 diabetes mellitus (T2DM) development. The reduction in lipid storage capacity in adipose tissue (AT) observed in obesity leads to an increase in NEFA in the bloodstream and their influx into muscle, pancreas and liver. This process leads to insulin resistance, reduced glucose uptake, increased glucose synthesis in the liver, reduction in the synthesis and insulin release in the pancreas, and consequent hyperglycaemia, characteristic of T2DM.

The excess of lipids in the bloodstream and their accumulation in organs, such as the pancreas, liver and muscle, seem to contribute to the development of insulin resistance and reduced secretion of insulin in overweight individuals. Ferrannini et al. (Reference Ferrannini, Barrett and Bevilacqua30) assessed the acute effect of increased NEFA concentration on glucose uptake and found that NEFA infusion in hyperinsulinaemic and normoglycaemic individuals had caused a reduction in glucose uptake. A similar result was observed in subjects with hyperglycaemia and hyperinsulinaemia. On the other hand, in individuals with hyperglycaemia, hypoinsulinaemia and hyperglucagonaemia (simulation of the diabetic condition), the infusion did not affect glucose uptake, but stimulated its production. The authors concluded that in appropriate insulin concentrations, increased concentration of NEFA in the blood competed with glucose during uptake by peripheral tissues, regardless of the presence of hyperglycaemia and, when insulin is deficient (diabetes), the excess of lipids in the bloodstream can contribute to hyperglycaemia, given the increase in glucose synthesis.

Taking into consideration that NEFA may contribute to inhibiting the function of pancreatic β cells, a study(Reference Zhou, Ling and Grill31) demonstrated that exposure of rat islets to palmitate raised the TAG content to 70 % in these structures after 6 h cell culturing, and 200 % after 48 h. This increase was associated with the inhibition of insulin secretion. A similar result was found in a study on human pancreatic islets, whose cell cultures exposed to palmitate or oleate had inhibited insulin secretion and proinsulin synthesis(Reference Zhou and Grill32). A possible explanation is that the addition of palmitate directs the metabolism of β cells to lipid synthesis by increasing the expression of enzymes involved in this process (glycerol-3-phosphate acyltransferase, diacylglycerol acyltransferase and hormone-sensitive lipase)(Reference Briaud, Harmon and Kelpe33).

NEFA represent an important energy source for the skeletal muscle and this organ has insulin resistance due to the increased lipid content in muscle fibres. One of the hypotheses for muscle insulin resistance was proposed by Randle et al. (1963) cited by Tabidi(Reference Tabidi34). They postulated that increased NEFA oxidation causes elevation of acetyl-CoA:CoA and NADH:NAD+ ratios in the mitochondria, providing the inactivation of pyruvate dehydrogenase. As a result of the increase in acetyl-CoA, the citrate concentration increases, resulting in inhibition of phosphofructokinase and accumulation of glucose-6-phosphate, which, in turn, inhibits hexokinase II reducing glucose uptake. An alternative hypothesis was suggested by Roden et al. (1996) cited by Kovacs & Stumvoll(Reference Kovacs and Stumvoll35), who described the increase in NEFA in plasma inducing insulin resistance through inhibition of glucose transport and phosphorylation, given the reduction in phosphatidylinositol 3-kinase activity associated with insulin receptor substrate-1. It is suggested that insulin resistance associated with NEFA involves blocking intracellular signalling by insulin due to fatty acid by-products.

As TAG content correlates with insulin resistance in skeletal muscle, Goodpaster et al. (Reference Goodpaster, Theriault and Watkins36) assessed whether worsening of insulin resistance could result from the increase in TAG, and whether these lipids would be increased in muscle fibres of obese individuals. The study revealed that lipid content in muscle fibres was greater in obese individuals with T2DM than in eutrophic individuals; however, it was not different in eutrophic individuals with T2DM. The authors also found that weight reduction contributed to the decrease in lipid content in muscle cells.

About 80 % of endogenous glucose production occurs in the liver and it is responsible for increased blood glucose concentration during the fasting period. The endogenous production of glucose occurs in T2DM in spite of hyperinsulinaemia. One of the consequences of the increase in NEFA flow for the liver in T2DM is the inhibition of insulin suppression of glucose production(Reference Kovacs and Stumvoll35). D’Adamo et al. (Reference D’Adamo, Cali and Weiss37) assessed the role of hepatic lipid accumulation in adolescents and found that the group of individuals with an elevated liver fat percentage (>5·5 %) had exhibited lower insulin secretion and sensitivity, and reduced suppression of endogenous glucose production. A similar result was found by Koska et al.(Reference Koska, Stefan and Permana38) in a study conducted with adults, whose liver lipid content was a predictor of reduced suppression of liver glucose synthesis mediated by insulin.

Thus, an ectopic deposition of NEFA influences the metabolic balance of nutrients. Possibly the accumulation of fat in other organs is favoured by the density increasing of the extracellular matrix that composes the AT. This characteristic reduces the adipocytes’ ability to store the excess of nutrients. Collagen VI is a protein that appears to be involved in the organisation of the matrix architecture. The reduction in gene expression that encodes it leads to the development of larger adipocytes, i.e. it enhances the fat storage capacity, reduces fibrosis and inflammation, and improves macronutrient homeostasis. A comparison between this characteristic and metabolically healthy obese individuals can be defined, once such individuals have mechanisms that lead to lower visceral fat deposition, fibrosis and subclinical inflammation reduction, and reductions in glucose and lipid concentrations in the blood. However, metabolically healthy obese generally present lower adipocytes when compared with unhealthy obese. Thus, the relationship between hypertrophy of fat cells and improvement of the metabolic profile is difficult to draw. A mechanism that can be thought of is the possible relationship between adipocyte hyperplasia, which results in many small fat cells, and the maintenance of glucose uptake and the secretion of adipokines at normal levels(Reference Rosen and Spiegelman39).

Gastaldelli et al. (Reference Gastaldelli, Cusi and Pettiti40) assessed the relationship between hepatic and visceral fat accumulation, and insulin resistance and hepatic gluconeogenesis. The authors found that excess visceral AT increased gluconeogenesis. Both visceral AT and hepatic fat accumulation were associated with insulin resistance. On the other hand, medications such as pioglitazone and metformin can improve insulin sensitivity by reducing intracellular TAG content in the liver and muscle, although the mechanism is still unknown(Reference Teranishi, Ohara and Maeda41). It is known that treatment with thiazolidinedione improves the metabolic profile of obese patients and one possible explanation for this result is the increase in the number of adipocytes and body adiposity(Reference Rosen and Spiegelman39). In addition to increasing hepatic glucose production, NEFA increase the production of VLDL and reduce the removal of insulin by the liver, causing hyperlipidaemia and hyperinsulinaemia(Reference Goossens1). All these results explain the intrinsic relationship between obesity and T2DM development.

Importance of vascularisation in adipose tissue

Metabolically, the dense network of blood vessels present in AT serves for the systematic transport of lipids towards the adipocytes. On the other hand, these vessels also carry adipokines and adipocyte nutrients to meet the metabolic and physiological demands(Reference Rutkowski, Davis and Scherer42).

Changes in AT blood flow can affect lipid storage in this organ, contributing to the increase in the amount of this nutrient in other tissues. AT blood flow controls, for example, the supply of TAG-rich lipoproteins to LPL, which is responsible for hydrolysing these lipids to NEFA and glycerol. It has been demonstrated that NEFA blood flow is reduced during the fasting period(Reference Goossens1). A study conducted by Potts et al. (Reference Potts, Coppack and Fisher43) showed that the release of AT lipids is reduced in obese individuals when compared with eutrophic individuals, both in the fasting and postprandial periods. This result reveals that impaired postprandial blood flow is associated with insulin resistance, which is partially explained by the decrease in TAG uptake in this period. These lipids remain longer in the circulation, which, according to Nellemann et al. (Reference Nellemann, Gormsen and Christiansen44), implies continuous NEFA availability to other organs. These authors found an association between plasma insulin and the greatest deposition of TAG from VLDL into abdominal subcutaneous AT of obese women. The relevance of the blood flow to lipid metabolism was also assessed in a study based on adrenaline infusion used in healthy individuals. It was found that adrenaline caused significant increase in AT blood flow and NEFA efflux from this tissue(Reference Samra, Simpson and Clark45).

Metabolic AT flexibility represents protection against lipotoxicity in other organs caused by excess energy intake(Reference Sotorník8), mainly after meals(Reference Ruge, Hodson and Cheeseman46). In order to guarantee this protection, the expansion and the reduction in fat mass also depend on the circulation present in the AT. Local hypoxia occurs when blood vessels are insufficient. Thus, microcirculation of AT is required for the expansion of adipose mass, not only due to its ability to prevent hypoxia, but as a potential entry point of adipocyte progenitors into white AT. The network of blood capillaries also contributes to immune response. An example is that the macrophages heading into AT have multiple functions: they remove necrotic adipocytes, which lead to the formation of foam cells; release pro-inflammatory mediators; and contribute to angiogenesis(Reference Rutkowski, Davis and Scherer42).

The adequate regulation of AT blood flow ensures the communication with other systems and the occurrence of reactions to meet the energy needs of the organism. It is worth noting that these flow modifications involve the initial stages of obesity and take part in the aggravation of disorders associated with this disease.

Relationship between adipocyte size and insulin resistance

The relationship between adipocyte size and insulin resistance has been studied for more than 40 years. Salans et al. (Reference Salans, Knittle and Hirsch47) compared insulin sensitivity of AT in obese and non-obese individuals with respect to cell size. It was found that responsiveness to insulin was higher in smaller-sized cells. These authors reported that insulin sensitivity had been restored after weight loss and consequent decrease in adipocyte size. In this way, the increase in body fat correlates with adipocyte hypertrophy and reduced insulin sensitivity. It should be noted that the increase in adipocyte size, especially in the abdominal area, has been observed in individuals with T2DM(Reference Lönn, Mehlig and Bengtsson48).

Adipocyte hypertrophy may be due to the impairment of new cell differentiation(Reference Goossens1). In this sense, one factor that leads to the development of T2DM seems to be the failure of the cell differentiation mechanism. This fact occurs because existing cells accumulate more TAG and increase their volume in the absence of new adipocytes, gradually becoming insensitive to insulin. Corroborating this hypothesis, Varlamov et al. (Reference Varlamov, Somwar and Cornea49) observed that small adipocytes of non-diabetic rhesus monkeys responded to insulin by increasing lipid uptake, whereas adipocytes of diameter larger than 80–100 µm were resistant to insulin. It seems that when cell size reaches a critical threshold, adipocytes decrease the transport of fatty acids stimulated by insulin to AT. This negative feedback can protect the adipocytes against excessive lipid accumulation and restrict the expansion of AT, which leads to obesity and associated metabolic complications. In this way, a potential association between adipocyte size and the development and progression of insulin resistance may be the reduction of NEFA uptake in AT.

As a consequence of lower fatty acid uptake, influx into the liver and the accumulation in this organ can lead to the production of endogenous glucose, thus exacerbating insulin resistance. Koska et al. (Reference Koska, Stefan and Permana38) found that the increase in lipid content in the liver may be associated with hypertrophic obesity, and visceral adiposity increase with peripheral and liver insulin resistance.

This way, what could the reduced NEFA transport due to the lack of stimulus generated by insulin in hypertrophic adipocytes cause? In contact with its receptor, insulin promotes a cascade of intracellular reactions that direct the vesicles containing GLUT4 glucose transporters to the cell membrane. A study conducted by Franck et al. (Reference Franck, Stenkula and Ost50) found no increase in the amount of GLUT4 in the plasma membrane of human hypertrophic adipocytes after stimulation with insulin; however, a twofold increase was observed in the amount of GLUT4 in the cells of smaller diameter in the same individual. This result suggests that the number of receptors exposed on the cell surface is limited and, considering the cell proportions, lipolysis can be enabled in hypertrophic cells to the detriment of lipogenesis due to glucose uptake stabilisation, even in the presence of insulin.

The relationship between adipocyte hypertrophy and insulin resistance is also evidenced by the restoration of GLUT4 expression and insulin sensitivity increase, as demonstrated in a study conducted by Koenen et al. (Reference Koenen, Tack and Kroese51). They found that treatment with pioglitazone (45 mg/d), a type of TZD, improved insulin sensitivity (placebo: 0·35 (sd 0·16) μmol/kg x min per milliunit per litre; pioglitazone: 0·53 (sd 0·16) μmol/kg x min per milliunit per litre, P<0·001), which was accompanied by an increase in the surface area of subcutaneous adipocytes (placebo: 2323 (sd 725) μm2; pioglitazone: 2821 (sd 885) μm2, P=0·03), and GLUT4 expression in AT. However, it is worth mentioning that there is a need to assess the trafficking of this receptor to the plasma membrane of fat cells, in order to confirm whether the improvement in sensitivity is due to the increase in the number or the action of these receptors. Still, TZD seems to contribute to the emergence of new pre-adipocytes originating from bone marrow precursors and stimulate their differentiation into mature adipocytes(Reference Goossens1).

Although the relationship between increased prevalence of chronic diseases, such as T2DM and non-alcoholic hepatic steatosis with increased weight, there is a subpopulation of obese individuals that seems to be protected or more resistant to the development of obesity-related metabolic changes(Reference Primeau, Coderre and Karelis52). It is estimated that up to 30 % of obese individuals are metabolically healthy and may be protected against the morbidity and mortality associated with excess weight; however, the factors responsible for this phenomenon are unknown. A study conducted by O’Connell et al. (Reference O’Connell, Lynch and Cawood53) revealed that the size of omental adipocytes in obese metabolically healthy individuals is smaller than the size of adipocytes in unhealthy individuals. Still, the size of these adipocytes positively correlated with the degree of insulin resistance (r 0·73; P<0·0005), concentration of TAG (r 0·65; P<0·0005), TAG:HDL ratio (r 0·67; P<0·0005) and glycated Hb (HbA1c) (r 0·50; P<0·005). The size of omental adipocytes was a predictor of the progression of hepatic steatosis to fibrosis, a process that has not been observed in metabolically healthy obese individuals.

Role of hypoxia in the development of insulin resistance

Insulin resistance is often associated with sleep apnoea and respiratory overload triggered by obesity. This process occurs because apnoea and overload cause intermittent cycles of hypoxia, resulting from periodic collapses of the airways during sleep(Reference Goossens1). Additionally, studies on adipocyte biology have allowed inferring that hypoxia negatively affects tissue function(Reference Ye, Gao and Yin54, Reference Bonsignore and Eckel55). In this way, which is the relationship between AT hypoxia and insulin resistance?

The increase in adipocyte size (up to 140–180 µm) observed in obesity causes hypoxia. The reason is the inadequate diffusion of oxygen, which would occur efficiently at a distance of approximately 100 µm from the blood vessel(Reference Goossens1). It is suggested that this situation may occur due to reduced AT blood flow, which has already been observed in mice by Hosogai et al. (Reference Hosogai, Fukuhara and Oshima56).

Hypoxia induces angiogenesis, which in turn stimulates more tissue expansion; however, the formation of new vessels is not enough to maintain AT growth(Reference Rutkowski, Davis and Scherer42, Reference Halberg, Khan and Trujillo57). Thus, hypoxia has become indicative of metabolic disorder, since the increase in AT results in elevation of the concentration of the α-subunit of the transcription by hypoxia-inducible factor 1 (HIF-1). This factor, in turn, stimulates the expression of adipokines and factors involved in inflammation, which have been implicated in the development of insulin resistance. It is worth mentioning that hypoxia also leads to an increased expression of genes involved in glucose metabolism and tissue fibrosis blocks pre-adipocyte differentiation(Reference Rutkowski, Davis and Scherer42, Reference Halberg, Khan and Trujillo57) (Fig. 3).

Fig. 3 Hypoxia and insulin resistance. The increase in adipocyte size observed in obesity leads to tissue hypoxia. Hypoxia induces angiogenesis and increased tissue expansion; however, the formation of new vessels is not enough to maintain adipose tissue (AT) growth. The increase in AT promotes the elevation of inflammatory cytokine expression, which has been related to the development of insulin resistance. Hypoxia has also been related to the inhibition of insulin signalling due to the reduction in phosphorylation of its receptor, thus causing hyperglycaemia. MCP-1, chemokine (C-C motif) ligand 2 (CCL2), also referred to as monocyte chemotactic protein-1.

Cells that suffer hypoxia also feature adaptive responses which are independent of hypoxia inducible factor 1α subunit (HIF-1α). It has been reported that the response of badly folded proteins is activated in the presence of hypoxia and contributes to cellular adaptation to this stress. Newly synthesised proteins of the secretory pathway and proteins of the membrane are folded correctly and organised by the chaperones of the granular endoplasmic reticulum. However, hypoxia causes the accumulation of badly folded proteins in the endoplasmic reticulum, resulting in the reticulum stress(Reference Hosogai, Fukuhara and Oshima56).

Chen et al. (Reference Chen, Cao and Han58) tested Sprague–Dawley rats to confirm the hypothesis that GLUT4 changes in intra-abdominal AT caused by intermittent hypoxia could facilitate the emergence of peripheral insulin resistance. These researchers found that the group submitted to intermittent hypoxia exhibited increased plasma insulin concentration in the fasting period (245·07 (sd 53·89) pg/ml v. 168·63 (sd 38·70) pg/ml, P=0·038) and a reduced amount of GLUT4 mRNA, as well as GLUT4 protein expression (0·002 (sd 0·002) v. 0·039 (sd 0·009), P<0·001; 0·642 (sd 0·073) v. 1·000 (sd 0·103), P=0·035) when compared with the rats of the control group. Quantification of GLUT4 is of relevant interest in order to understand the mechanisms by which hypoxia leads to insulin resistance.

Regazzetti et al. (Reference Regazzetti, Pascal and Grémeaux59) assessed whether the phenomenon that leads to insulin resistance may be due to failures in the intracellular signalling pathway of this hormone. The signalling triggered by hypoxia was modulated in human and murine adipocytes by means of incubation in low oxygen concentration (1 % O2) or HIF-1 expression. Insulin signalling was monitored through the phosphorylation state of several important proteins in this pathway and glucose transport. It was found that hypoxia inhibited insulin signalling, which was demonstrated by the reduction in phosphorylation of the insulin receptor and the reversal of this process under normal oxygen conditions.

In addition to apnoea, there are other arguments in favour of the hypothesis of hypoxia, such as: cardiac output and blood flow to AT do not increase in obese individuals, despite the expansion of fat mass; and obese individuals do not exhibit increased postprandial blood flow, as occurs in eutrophic individuals(Reference Trayhurn, Wang and Wood60).

The set of information obtained about hypoxia suggests that adipogenesis inhibition and TAG synthesis may be a mechanism for the increase in NEFA in the circulation of obese individuals, which contributes to the triggering of insulin resistance. This information can help understand the beneficial effects of energy restriction and performance of periodic physical exercise. Evidence shows that weight reduction improves tissue oxygenation and reduces inflammation(Reference Ye61). This way, increased AT oxygenation may be a new strategy in the treatment of inflammation and insulin resistance associated with obesity.

Adipose tissue as an endocrine organ

The ability of AT to secrete a variety of adipokines which can perform as autocrine, paracrine and systemic mechanisms has been discovered in the last 15 years. These chemical mediators revolutionised the concepts about the biological function of AT. There is a consensus that this tissue does not only supply and store energy, but it is also a dynamic and central organ that regulates appetite, food intake, glucose availability and energy expenditure(Reference Goossens1, Reference Fonseca-Alaniz, Takada and Alonso-Vale14, Reference Chopra, Siddhu and Tandon62).

Due to the diversity of adipokines and the variety of functions already identified, it can be said that they comprise proteins related to the immune system (for example, TNF-α and IL-6), growth factors (for example, transforming growth factor-β (TGF-β)) and proteins of the alternative complement pathway (adipsin). Still, there are also adipokines involved in blood pressure regulation (angiotensinogen), blood clotting (plasminogen activator inhibitor-1; PAI-1), glucose homeostasis (adiponectin, resistin, visfatin and leptin) and angiogenesis (vascular endothelial growth factor; VEGF), among several other actions(Reference Fonseca-Alaniz, Takada and Alonso-Vale14). Besides the fact that AT performs its own metabolic activities, the adipocytes release signals to other tissues and regulate their metabolism. On the other hand, AT expresses numerous receptors allowing the response to afferent signals, such as hormones and signals from the central nervous system(Reference Goossens1).

IL-6, TNF-α, and the complement factors B, C3 and D (adipsin) are adipokines with immune function. They are produced by adipocytes in response to infectious or inflammatory stimuli. Although some of these molecules have mainly autocrine and paracrine actions, some of them contribute significantly to systemic inflammation(Reference Costa and Duarte63).

IL-6 is a cytokine with pro-inflammatory and endocrine actions. It is present in physiological situations of visceral AT, being secreted by many cells, including adipocytes and vascular fraction cells. Like TNF-α, IL-6 inhibits LPL expression, stimulating lipolysis and hepatic lipid secretion, promoting hypertriacylglycerolaemia. It is also involved in the suppression of adiponectin expression(Reference Ramalho and Guimarães6, Reference Prado, Lofrano and Oyama7). On the other hand, it stimulates the production of acute-phase proteins in the liver (C-reactive protein, fibrinogen, haptoglobin, complement factor 3 and serum amyloid-A protein)(Reference Prado, Lofrano and Oyama7, Reference Zulet, Puchau and Navarro64).

The secretion of these substances is increased in adipocytes of obese individuals and has an important role, both as circulating hormones and local regulators of insulin action(Reference Chopra, Siddhu and Tandon62, Reference Zulet, Puchau and Navarro64, Reference Kern, Ranganathan and Li65). Ye et al. (Reference Ye, Gao and Yin54) studied ob/ob mice and found that hypoxia was associated with an increased expression of inflammatory genes (TNF-α, IL-1, IL-6 and TGF-β), chemokines (macrophage migration inhibitory factor; MIF), extracellular enzyme (matrix metalloproteinase-9; MMP-9) and macrophage markers proteins (CD11 and F4/80), suggesting an increase in inflammation and macrophage infiltration in obesity. In that study, the authors found an association between inflammation and hypoxia in mice whose obesity was induced by feeding. These results suggest that chronic inflammation is associated with hypoxia in AT of obese mice.

IL-18 is a potent pro-inflammatory mediator, with chemotactic properties in mononuclear cells. This cytokine is produced and secreted by human adipocytes, as well as by skeletal muscle. Its primary production occurs in non-fatty AT cells(Reference Zulet, Puchau and Navarro64, Reference Bruun, Stallknecht and Helge66). It is considered a key mediator in subclinical inflammation associated with abdominal obesity and its complications(Reference Zulet, Puchau and Navarro64).

Complement molecules were the first adipokines identified (adipsin or factor D) in AT. There is also production of factors B, C3 and D. The presence of the factors B and D is required for the synthesis of factor C3a. This protein is involved in TAG synthesis and storage and its deficiency in rats is associated with decreased body fat and increased insulin sensitivity. It should be noted that adipsin levels increase due to food intake(Reference Costa and Duarte63).

PAI-1 stands out in the group of molecules with cardiovascular function. It is a protein that promotes thrombus formation and rupture of unstable atherogenic plaques(Reference Fonseca-Alaniz, Takada and Alonso-Vale14). It is primarily produced in the liver, but also in AT, and this tissue is its main source in obesity. PAI-1 production is stimulated by insulin and corticoids and its expression is regulated by PPAR. PAI-1 levels correlate with visceral fat and it is involved in the development of CVD(Reference Costa and Duarte63).

Adiponectin stands out among the molecules with metabolic function that participate in energy homeostasis. It is a protein produced specifically by adipocytes and its mRNA is decreased in obesity and insulin resistance(Reference Ye67). This adipocin enhances the action of insulin in the liver and reduces hepatic glucose production. It also induces the oxidation of fats, reducing TAG levels in liver and muscle. Its anti-inflammatory action is a result of decreased synthesis and action of TNF-α and IL-6, and induction of IL-10 production. TZD increase adiponectin, which is another mechanism responsible for increased insulin sensitivity associated with the use of these drugs(Reference Ye61).

Resistin is a mediator that induces insulin resistance. Currently, it is known that its expression in human adipocytes is reduced, but it is high in monocytes and macrophages. In animal models, high concentrations of resistin are associated with insulin resistance and inhibition of pre-adipocyte differentiation. On the other hand, visfatin is mainly produced by visceral AT and has insulin-mimetic action, since by binding to the insulin receptor it promotes its activation(Reference Costa and Duarte63).

Leptin is a molecule known as the paradigm of the endocrine function in AT and it is vital in regulating energy deposits. Leptin is a peptide whose synthesis predominates in AT. Its production in adipocytes is regulated by insulin and its concentration correlates positively with AT mass. The binding of leptin to hypothalamic receptors triggers the transmission of information concerning AT mass and existing energy deposits. As a consequence, the efferent response triggered by the sympathetic nervous system determines the reduction of anabolism and increased energy expenditure(Reference Waki and Tontonoz68). In addition, one of the peripheral actions of leptin is the reduction in insulin synthesis and secretion, thus establishing an adipo-insular axis.

A study conducted by Blažetić et al. (Reference Blažetić, Labak and Viljetić69) using an animal model revealed increased distribution of leptin receptors (Ob-R) in the lateral hypothalamic nucleus, but without effect on the arcuate nucleus resulting from a fat-rich diet. This way, in obesity, despite the high concentration of circulating leptin and possible increase in the number of receptors in the brain, leptin does not induce the expected response of decreased intake and increased energy expenditure. As the outcome, there is resistance to the action of leptin, which can lead to interruption of the adipo-insular axis and maintenance of insulin secretion.

Whether the increase in adipocyte volume leads to the expression of inflammatory cytokines has not yet been elucidated, because adipocyte size is associated with this feature. In order to discuss this issue, Ye et al. (Reference Ye, Gao and Yin54) assessed the mechanical strain on the cell surface (using compressed air or vacuum condition) and found that adipocytes exhibited changes in endocrine function under vacuum conditions. Since vacuum conditions are associated with low oxygen concentration, the authors also confirmed the hypothesis that hypoxia influences AT.

Inflammation, macrophage infiltration and insulin resistance: a continuous cycle

AT is a heterogeneous organ that contains different cellular types including mature adipocytes, pre-adipocytes, endothelial cells, vascular smooth muscle cells, leucocytes, monocytes and macrophages(Reference Goossens1). Thus, what is the origin of adipokines expressed in AT? Each adipocyte and other TA cells produce a small amount of substances, including cytokines and acute-phase proteins that directly or indirectly increase the production and circulation of factors related to inflammation. However, due to the fact that AT is considered one of the largest organs in the body, the pool of these factors secreted into the circulation can have a great impact on bodily functions(Reference Prado, Lofrano and Oyama7).

Two mechanisms are suggested in the literature to explain the low-intensity chronic inflammatory process, also known as ‘metaflammation’ (metabolic inflammation), which is coordinated by cells in response to excess nutrients and energy(Reference Gregor and Hotamisligil70). It is worth pointing out that when it comes to obesity, not only the amount of AT should be taken into consideration, but also the type of adiposity. Adipocytes of subcutaneous AT are highly functional due to their greater ability to store energy, which makes them different from adipocytes found in visceral AT, which are less functional and whose tissue has a greater amount of macrophages(Reference Goyal, Nimmakayala and Zonszein2).

The first suggested mechanism is AT hypoxia and the second is macrophage infiltration into AT. In AT expansion, the increase in cell volume and consequent remoteness of adipocytes from the proximity of blood vessels can turn them hypoxic. Some authors suggest that the onset of hypoxia stimulates the release of inflammatory cytokines, chemokines and angiogenic factors (VEGF) as a way to increase the blood flow and stimulate vascularisation(Reference Ramalho and Guimarães6). Cytokines and chemokines, especially chemokine (C-C motif) ligand 2 also referred to as monocyte chemotactic protein-1 (MCP-1), lead to an increased number of circulating monocytes and infiltration into AT, due to increased expression of adhesion molecules in the endothelium of blood vessels. It is worth mentioning that MCP-1 is produced by resident macrophages, endothelial cells and adipocytes. It has been reported that circulating concentrations of chemokines are elevated in obese and diabetic individuals; however, they seem to diminish as a consequence of weight loss(Reference Goossens1).

The basic mechanisms of low-intensity inflammatory processes observed in obesity are not fully understood, but it is known that macrophage infiltration can be an important source of pro-inflammatory adipokines synthesised locally(Reference Luca and Olefsky71). This synthesis is mainly triggered by stress of the endoplasmic reticulum. This deregulation in the synthesis and secretion of adipokines may have local and systemic effects. It has been shown that TNF-α inhibits the differentiation of adipocyte precursors and, similarly, IL-6 also inhibits adipocyte differentiation. Additionally, it has been observed that TNF-α induces apoptosis in pre-adipocytes and mature cells. These effects may result in decreased body fat storage capacity, and increased glucose and NEFA concentration, leading to insulin resistance(Reference Goossens1) and T2DM. This process occurs due to the inhibition of insulin receptor signalling in peripheral tissues by these fatty acids, concomitant increase of reactive oxygen species, and production of inflammatory cytokines in pancreatic β cells, promoting the attraction of immune cells to the organ(Reference Donath72) and reduction in insulin synthesis. At the same time, NEFA induce increased expression of MCP-1 and IL-6 in pre-adipocytes, in a greater amount than in mature adipocytes(Reference Dordevic, Konstantopoulos and Cameron-Smith73).

The relationship between macrophage infiltration and insulin resistance in obesity occurs in an intriguing way. MCP-1 expression and secretion by pre-adipocytes can be stimulated by TNF-α, insulin, IL-6 and growth hormone, whereas its secretion by mature adipocytes is reduced by stimuli that increase insulin sensitivity, such as adiponectin and treatment with TZD. This way, changes in the secretion of adipokines can modulate MCP-1 synthesis and this, in turn, can influence macrophage infiltration into AT. Studies(Reference Kanda, Tateya and Tamori74, Reference Weisberg, Hunter and Huber75) showed that CCR2 (receptor for MCP-1) and MCP-1 knockout mice subjected to treatment with a hyperlipidic diet exhibited reduced macrophage infiltration into AT, reduction in pro-inflammatory gene expression, hepatic TAG content and improvement in insulin sensitivity when compared with the mice of the control group. In this way, it is possible to infer that MCP-1 plays an important role in macrophage infiltration into AT and may contribute to the development of insulin resistance. Corroborating these results, the study conducted by Kanda et al. (Reference Kanda, Tateya and Tamori74) showed that MCP-1 overexpression in AT of GM mice increased macrophage infiltration and contributed to the development of insulin resistance.

In the inflammatory context, macrophages present in AT suffer changes in number, tissue distribution and function, thus enlarging the subclinical inflammation. These resident cells are proportionately increased in number and size in AT according to BMI and may represent about 60 % of this tissue components. Given the activity of macrophages in metabolic inflammation, Ye et al. (Reference Ye, Gao and Yin54) found that inflammatory gene expression in macrophages can be induced in response to inflammation. Peritoneal macrophages extracted from C57BL/6 mice with hypoxia treated in vitro had inflammatory genes significantly expressed. Three inflammatory genes (IL-6, MIF and MMP-9) were also induced by hypoxia in 3T3-L1 adipocytes. Thus, when macrophages are activated, they release biologically active cytokines, such as NO, TNFα, IL-6 and IL-1 that increase the production of acute-phase proteins (PAI-1, CRP and haptoglobin) which, in turn, contribute to systemic inflammation and insulin resistance. However, the activation of macrophages in areas of inflammation is typically temporary, giving way to repair processes that attempt to re-establish the local function of the tissue. In this way, macrophage infiltration into AT observed in obesity is due to increased infiltration of circulating monocytes(Reference Ramalho and Guimarães6, Reference Bruun, Stallknecht and Helge66, Reference Bruun, Helge and Richelsen76).

The hypoxic state can also lead to adipocyte death. In obese subjects, the adipocytes surrounded by macrophages exhibit rupture of the plasma membrane, dilated endoplasmic reticulum, cellular debris in the extracellular space, and small lipid droplets in the cytoplasm suggesting necrosis. It is thought that adipocyte death contributes not only to the recruitment of monocytes to AT via MCP-1, but also to its functional change, with formation of multinucleated giant cells(Reference Ramalho and Guimarães6, Reference Hauner77).

In this sense, the infiltration process may be a consequence and, at the same time, the cause of the chronic inflammatory state associated with obesity. The consequence is characterised by the induction of pro-inflammatory cytokine expression by adipocytes, which promotes macrophage infiltration into AT. The cause is characterised by the environment with low oxygen concentration, which makes the macrophages more active producing more cytokines, such as TNF-α and IL-1(Reference Ye61). Even though the initial stimulus for the recruitment of macrophages into AT arises from resident cells in this tissue, they can perpetuate an uninterrupted cycle of macrophage recruitment and production of pro-inflammatory adipokines along with adipocytes and other cell types, thus leading to a progressive loss of adipocyte function and development of insulin resistance related to obesity.

In response to the environment around them, the macrophages have different functional states. Macrophages present in AT of obese individuals can be found in the M1 state, i.e. pro-inflammatory expressing a wide variety of genes important for adhesion, migration and inflammation. However, after weight loss and consequent decrease in fat mass, there seems to be a phenotypic transition of macrophages to an anti-inflammatory state (M2), which is proven by the increased IL-10 expression(Reference Olefsky and Glass78). The adaptation is complex and depends on changes in IL-1, TNF-α and MCP-1 concentrations, and M1 macrophages. This phenotypic change is accompanied by changes in the number and distribution of macrophages in AT(Reference Ramalho and Guimarães6, Reference Surmi and Hasty79).

Various mechanisms are involved in the pathogenesis of insulin resistance linked to disorders caused by obesity. However, weight loss is the key factor to reverse the situation to a healthy state before the installation of T2DM. Weight reduction seems to influence not only adipokine concentrations, especially the increase in adiponectin and its receptors, whose effects are anti-diabetogenic but also macrophage infiltration revealed by the repolarisation of these cells in AT(Reference Olefsky and Glass78, Reference Lee and Kwak80).

Conclusions

When AT performs the function of ‘lipid storage organ’, it has great metabolic flexibility, which makes it possible to protect other organs against lipotoxicity. However, AT dysfunction observed in obesity is characterised by adipocyte hypertrophy, increased NEFA concentration, synthesis and inflammatory adipokine secretion, and macrophage infiltration, leading to insulin resistance due to the impairment of this hormone signalling in the liver, muscle and AT. As a result, the number of glucose receptors exposed in the plasma membrane is reduced, which compromises homeostasis and favours hyperglycaemia, which is a characteristic of type 2 diabetes. Thus, a broader understanding of obesity and its relationship with diabetes may be established. In this context, some points need to be further clarified:

  1. (1) How and what adipocyte maturation pathways are activated by excessive energy intake?

  2. (2) What are the mediators involved in cell differentiation in preadipocytes and what is the trigger for differentiation to happen?

  3. (3) How do the molecular mediators orchestrate adipocyte physiology in the disease and how can their action mechanisms be changed in order to restore health?

  4. (4) What are the changes that occur in AT as a result of excessive consumption of food and what do these changes imply in the dysfunction of other organs and metabolic changes?

  5. (5) How do adipokines act in the microenvironment of AT and in other tissues that constitute the body, and what are the answers developed by them with glucose homeostasis implications?

Although it may be complex, the network connecting obesity to diabetes emergence may allow different strategies to be created in order to prevent and treat these diseases. An example of this is that the effects of AT dysfunction on glucose homeostasis can be softened or prematurely reversed through the adoption of healthy habits that promote weight and body fat loss. It is worth mentioning that there is no consensus among studies that compare the effects of different amounts and quality of macronutrients, as well as the amount of body weight loss needed to change beneficially the inflammatory markers. Therefore, there is a need of further studies in this area.

Acknowledgements

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

M. V. A. had a role in the design, analysis and writing of the article. F. C. E. de O. and L. L. da C. were in charge of drafting the manuscript; F. C. E. de O., L. L. da C. and M. C. G. P. revised the first drafts. M. V. A. and L. L. da C. designed the figures. All authors critically reviewed the manuscript and approved the final version.

There are no conflicts of interest.

References

1.Goossens, GH (2008) The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 94, 206218.CrossRefGoogle ScholarPubMed
2.Goyal, A, Nimmakayala, KR & Zonszein, J (2014) Is there a paradox in obesity? Cardiol Rev 22, 163170.CrossRefGoogle Scholar
3.White, RT, Damm, D, Hancock, N, et al. (1992) Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 267, 92109213.CrossRefGoogle ScholarPubMed
4.Forsythe, LK, Wallace, JMW & Livingstone, MBE (2008) Obesity and inflammation: the effects of weight loss. Nutr Res Rev 21, 117133.CrossRefGoogle ScholarPubMed
5.Geraldo, JM & Alfenas, RCG (2008) Papel da dieta na prevenção e no controle da inflamação crônica – evidências atuais (Role of diet in the prevention and control of chronic inflammation – current evidence). Arq Bras Endocrinol Metab 52, 951967.CrossRefGoogle Scholar
6.Ramalho, R & Guimarães, C (2008) Papel do TA e dos macrófagos no estado de inflamação crónica associada à obesidade – implicações clínicas (Role of adipose tissue and macrophages in the state of chronic inflammation associated with obesity – clinical implications). Acta Med Port 21, 489496.Google Scholar
7.Prado, WL, Lofrano, MC, Oyama, LM, et al. (2009) Obesidade e adipocinas inflamatórias: implicações práticas para prescrição do exercício (Obesity and inflammatory adipokines: practical implications for exercise prescription). Rev Bras Med Esporte 15, 378383.CrossRefGoogle Scholar
8.Sotorník, R (2010) Adipose tissue blood flow and metabolic syndrome. Cas Lek Cesk 149, 155159.Google ScholarPubMed
9.Frühbeck, G, Méndez-Giménez, L, Fernández-Formoso, JA, et al. (2014) Regulation of adipocyte lipolysis. Nutr Res Ver 27, 6393.CrossRefGoogle ScholarPubMed
10.Crossno, JT Jr, Majka, SM, Grazia, T, et al. (2006) Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J Clin Invest 116, 32203228.CrossRefGoogle ScholarPubMed
11.Majka, SM, Fox, KE, Psilas, JC, et al. (2010) De novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific. Proc Natl Acad Sci U S A 107, 1478114786.CrossRefGoogle ScholarPubMed
12.Billon, N, Kolde, R, Reimand, J, et al. (2010) Comprehensive transcriptome analysis of mouse embryonic stem cell adipogenesis unravels new processes of adipocyte development. Genome Biol 11, R80.CrossRefGoogle ScholarPubMed
13.Dudakovic, A, Camilleri, ET, Lewallen, EA, et al. (2015) Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cells. J Cell Physiol 230, 5262.CrossRefGoogle ScholarPubMed
14.Fonseca-Alaniz, MH, Takada, J, Alonso-Vale, MIC, et al. (2007) O tecido adiposo como órgão endócrino: da teoria à prática (Adipose tissue as an endocrine organ: from theory to practice). J Pediatr 83, S192S203.CrossRefGoogle Scholar
15.Dudakovic, A, Camilleri, E, Riester, SM, et al. (2014) High-resolution molecular validation of self-renewal and spontaneous differentiation in clinical-grade adipose-tissue derived human mesenchymal stem cells. J Cell Biochem 115, 18161828.CrossRefGoogle ScholarPubMed
16.Perrini, S, Cignarelli, A, Ficarella, R, et al. (2009) Human adipose tissue precursor cells: a new factor linking regulation of fat mass to obesity and type 2 diabetes? Arch Physiol Biochem 115, 218226.CrossRefGoogle Scholar
17.Bosnakovski, D, Mizuno, M, Kim, G, et al. (2005) Isolation and multilineage differentiation of bovine bone marrow mesenchymal stem cells. Cell Tissue Res 319, 243253.CrossRefGoogle ScholarPubMed
18.Dicker, A, Camilleri, E, Riester, SM, et al. (2005) Functional studies of mesenchymal stem cells derived from adult human adipose tissue. Exp Cell Res 308, 283290.CrossRefGoogle ScholarPubMed
19.Peister, A, Mellad, JA, Larson, BL, et al. (2004) Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103, 16621668.CrossRefGoogle ScholarPubMed
20.Tang, W, Zeve, D, Suh, JM, et al. (2008) White fat progenitor cells reside in the adipose vasculature. Science 322, 583586.CrossRefGoogle ScholarPubMed
21.Sharma, AM & Staels, B (2007) Review: peroxisome proliferator-activated receptor γ and adipose tissue – understandinding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92, 386395.CrossRefGoogle ScholarPubMed
22.Lee, JE & Ge, K (2014) Transcriptional and epigenetic regulation of PPARγ expression during adipogenesis. Cell Biosci 4, 29.CrossRefGoogle ScholarPubMed
23.Kubota, N, Terauchi, Y, Miki, H, et al. (1999) PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4, 597609.CrossRefGoogle ScholarPubMed
24.Kersten, S (2002) Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 440, 223234.CrossRefGoogle ScholarPubMed
25.Way, JM, Harrington, WW, Brown, KK, et al. (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142, 12691277.CrossRefGoogle ScholarPubMed
26.Kersten, S, Mandard, S, Escher, P, et al. (2001) The peroxisome proliferators-activated receptor α regulates amino acid metabolism. FASEB J 15, 19711978.CrossRefGoogle Scholar
27.Spiegelman, BM & Enerbäck, S (2006) The adipocyte: a multifunctional cell. Cell Metab 4, 425427.CrossRefGoogle ScholarPubMed
28.Kadowaki, T, Hara, K, Yamauchi, T, et al. (2003) Molecular mechanism of insulin resistance and obesity. Exp Biol Med 288, 11111117.CrossRefGoogle Scholar
29.Trayhurn, P (2007) Adipocyte biology. Obes Rev 8, S41S44.CrossRefGoogle ScholarPubMed
30.Ferrannini, E, Barrett, EJ, Bevilacqua, S, et al. (1983) Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72, 17371747.CrossRefGoogle ScholarPubMed
31.Zhou, YP, Ling, ZC & Grill, VE (1996) Inhibitory effects of fatty acids on glucose-regulated B-cell function: association with increased islet triglyceride stores and altered effect of fatty acid oxidation on glucose metabolism. Metabolism 45, 981986.CrossRefGoogle ScholarPubMed
32.Zhou, YP & Grill, V (1995) Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 80, 15841590.Google ScholarPubMed
33.Briaud, I, Harmon, JS, Kelpe, CL, et al. (2001) Lipotoxicity of the pancreatic β-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 50, 315321.CrossRefGoogle ScholarPubMed
34.Tabidi, I (2009) The effect of glucose on cardiac AMP-activated protein kinase. PhD Thesis, University College London.Google Scholar
35.Kovacs, P & Stumvoll, M (2005) Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 19, 625635.CrossRefGoogle ScholarPubMed
36.Goodpaster, BH, Theriault, R, Watkins, SC, et al. (2000) Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 49, 467472.CrossRefGoogle ScholarPubMed
37.D’Adamo, E, Cali, AM, Weiss, R, et al. (2010) Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 33, 18171822.CrossRefGoogle ScholarPubMed
38.Koska, J, Stefan, N, Permana, PA, et al. (2008) Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am J Clin Nutr 87, 295302.CrossRefGoogle ScholarPubMed
39.Rosen, ED & Spiegelman, BM (2014) What we talk about when we talk about fat. Cell 156, 2044.CrossRefGoogle ScholarPubMed
40.Gastaldelli, A, Cusi, K, Pettiti, M, et al. (2007) Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133, 496506.CrossRefGoogle ScholarPubMed
41.Teranishi, T, Ohara, T, Maeda, K, et al. (2007) Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 56, 14181424.CrossRefGoogle ScholarPubMed
42.Rutkowski, JM, Davis, KE & Scherer, PE (2009) Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J 276, 57385746.CrossRefGoogle ScholarPubMed
43.Potts, JL, Coppack, SW, Fisher, RM, et al. (1995) Impaired postprandial clearance of triacylglycerol-rich lipoproteins in adipose tissue in obese subjects. Am J Physiol 268, E588E594.Google ScholarPubMed
44.Nellemann, B, Gormsen, LC, Christiansen, JS, et al. (2010) Postabsorptive VLDL-TG fatty acid storage in adipose tissue in lean and obese women. Obesity 18, 13041311.CrossRefGoogle ScholarPubMed
45.Samra, JS, Simpson, EJ, Clark, ML, et al. (1996) Effects of epinephrine infusion on adipose tissue: interactions between blood flow and lipid metabolism. Am J Physiol Endocrinol Metab 271, E834E839.CrossRefGoogle ScholarPubMed
46.Ruge, T, Hodson, L, Cheeseman, J, et al. (2009) Fasted to fed trafficking of fatty acids in human adipose tissue reveals a novel regulatory step for enhanced fat storage. J Clin Endocrinol Metab 94, 17811788.CrossRefGoogle ScholarPubMed
47.Salans, LB, Knittle, JL & Hirsch, J (1968) The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. J Clin Invest 47, 153165.CrossRefGoogle ScholarPubMed
48.Lönn, M, Mehlig, K, Bengtsson, C, et al. (2010) Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J 24, 326331.CrossRefGoogle ScholarPubMed
49.Varlamov, O, Somwar, R, Cornea, A, et al. (2010) Single-cell analysis of insulin-regulated fatty acid uptake in adipocytes. Am J Physiol Endocrinol Metab 299, E486E496.CrossRefGoogle ScholarPubMed
50.Franck, N, Stenkula, KG, Ost, A, et al. (2007) Insulin-induced GLUT4 translocation to the plasma membrane is blunted in large compared with small primary fat cells isolated from the same individual. Diabetologia 50, 17161722.CrossRefGoogle Scholar
51.Koenen, TB, Tack, CJ, Kroese, JM, et al. (2009) Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. J Clin Endocrinol Metab 94, 44534457.CrossRefGoogle ScholarPubMed
52.Primeau, V, Coderre, L, Karelis, AD, et al. (2011) Characterizing the profile of obese patients who are metabolically healthy. Int J Obes 35, 971981.CrossRefGoogle ScholarPubMed
53.O’Connell, J, Lynch, L, Cawood, TJ, et al. (2010) The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS ONE 5, e9997.CrossRefGoogle ScholarPubMed
54.Ye, J, Gao, Z, Yin, J, et al. (2007) Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 293, E1118E1128.CrossRefGoogle Scholar
55.Bonsignore, MR & Eckel, J (2009) Metabolic aspects of obstructive sleep apnoea syndrome. Eur Respir Rev 18, 113124.CrossRefGoogle ScholarPubMed
56.Hosogai, N, Fukuhara, A, Oshima, K, et al. (2007) adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56, 901911.CrossRefGoogle ScholarPubMed
57.Halberg, N, Khan, T, Trujillo, ME, et al. (2009) Hypoxia-inducible factor 1α induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 29, 44674483.CrossRefGoogle ScholarPubMed
58.Chen, L, Cao, ZL, Han, F, et al. (2010) Chronic intermittent hypoxia from pedo-stage decreases glucose transporter 4 expression in adipose tissue and causes insulin resistance. Chin Med J 123, 463470.Google ScholarPubMed
59.Regazzetti, C, Pascal, P, Grémeaux, T, et al. (2009) Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 58, 95103.CrossRefGoogle ScholarPubMed
60.Trayhurn, P, Wang, B & Wood, IS (2008) Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 100, 227235.CrossRefGoogle ScholarPubMed
61.Ye, J (2008) Role of adipose hypoxia in endocrine alterations: a possible new anti-inflammatory therapeutic target in obesity? Expert Rev Endocrinol Metab 3, 911.CrossRefGoogle ScholarPubMed
62.Chopra, M, Siddhu, A & Tandon, N (2014) Mechanism of leptin action, resistance and regulation of energy balance: a review. Asian J Multidiscip Stud 2, 224234.Google Scholar
63.Costa, JV & Duarte, JS (2006) Tecido adiposo e adipocinas (Adipose tissue and adipokines). Acta Med Port 19, 251256.Google ScholarPubMed
64.Zulet, MA, Puchau, B, Navarro, C, et al. (2007) Biomarcadores del estado de inflamatorio: nexo de unión con la obesidad y complicaciones asociadas (Biomarkers of the inflammatory state: link with obesity and associated complications). Nutr Hosp 22, 511527.Google Scholar
65.Kern, PA, Ranganathan, S, Li, C, et al. (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280, E745E751.CrossRefGoogle ScholarPubMed
66.Bruun, JM, Stallknecht, B, Helge, JW, et al. (2007) Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol 157, 465471.CrossRefGoogle ScholarPubMed
67.Ye, J (2009) Emerging role of adipose tissue hypoxia in obesity and insulin. Int J Obes 33, 5466.CrossRefGoogle ScholarPubMed
68.Waki, H & Tontonoz, P (2007) Endocrine functions of adipose tissue. Annu Rev Pathol Mech Dis 2, 3156.CrossRefGoogle ScholarPubMed
69.Blažetić, S, Labak, I, Viljetić, B, et al. (2014) Effects of high fat diet, ovariectomy, and physical activity on leptin receptor expression in rat brain and white fat tissue. Croat Med J 55, 228238.CrossRefGoogle ScholarPubMed
70.Gregor, MF & Hotamisligil, GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29, 415445.CrossRefGoogle ScholarPubMed
71.Luca, C & Olefsky, JM (2006) Stressed out about obesity and insulin resistance. Nat Med 12, 4142.CrossRefGoogle ScholarPubMed
72.Donath, MY (2014) Targeting inflammation in the treatment type 2 diabetes: time to start. Nat Rev Drug Discov 13, 465476.CrossRefGoogle ScholarPubMed
73.Dordevic, AL, Konstantopoulos, N & Cameron-Smith, D (2014) 3T3-L1 preadipocytes exhibit heightened monocyte-chemoattractant protein-1 response to acute fatty acid exposure. PLOS ONE 9, e99382.CrossRefGoogle ScholarPubMed
74.Kanda, H, Tateya, S, Tamori, Y, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116, 14941505.CrossRefGoogle ScholarPubMed
75.Weisberg, SP, Hunter, D, Huber, R, et al. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116, 115124.CrossRefGoogle ScholarPubMed
76.Bruun, JM, Helge, JW, Richelsen, B, et al. (2006) Diet and exercise reduce low-grade inflammation and macrophage infiltration on adipose tissue but not in skeletal muscle in severely obese subjects. Am J Phisiol Endocrinol Metab 290, E961E967.CrossRefGoogle Scholar
77.Hauner, H (2010) Adipose tissue inflammation: are small or large fat cells to blame? Diabetologia 53, 223225.CrossRefGoogle ScholarPubMed
78.Olefsky, JM & Glass, CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72, 219246.CrossRefGoogle ScholarPubMed
79.Surmi, BK & Hasty, AH (2008) Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol 3, 545556.CrossRefGoogle ScholarPubMed
80.Lee, S & Kwak, HB (2014) Effects of interventions on adiponectin and adiponectin receptors. J Exerc Rehabil 10, 6068.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1 Influence of positive energy balance on adipogenesis. An excess of energy nutrients makes pre-adipocytes increase the expression of mediators associated with the accumulation of intracellular TAG transforming them into mature adipocytes. GPDH, glycerol-3-phosphate dehydrogenase; LPL, lipoprotein lipase; aP2, adipocyte protein 2 – carrier protein for fatty acids.

Figure 1

Fig. 2 Accumulation of NEFA in the blood and relationship with type 2 diabetes mellitus (T2DM) development. The reduction in lipid storage capacity in adipose tissue (AT) observed in obesity leads to an increase in NEFA in the bloodstream and their influx into muscle, pancreas and liver. This process leads to insulin resistance, reduced glucose uptake, increased glucose synthesis in the liver, reduction in the synthesis and insulin release in the pancreas, and consequent hyperglycaemia, characteristic of T2DM.

Figure 2

Fig. 3 Hypoxia and insulin resistance. The increase in adipocyte size observed in obesity leads to tissue hypoxia. Hypoxia induces angiogenesis and increased tissue expansion; however, the formation of new vessels is not enough to maintain adipose tissue (AT) growth. The increase in AT promotes the elevation of inflammatory cytokine expression, which has been related to the development of insulin resistance. Hypoxia has also been related to the inhibition of insulin signalling due to the reduction in phosphorylation of its receptor, thus causing hyperglycaemia. MCP-1, chemokine (C-C motif) ligand 2 (CCL2), also referred to as monocyte chemotactic protein-1.